Wedbush raised the firm’s price target on Tourmaline Bio (TRML) to $43 from $42 and keeps an Outperform rating on the shares. All key ...
Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.
Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total ...
Tourmaline Bio (NASDAQ:TRML – Get Free Report) had its price objective lifted by analysts at HC Wainwright from $49.00 to $50.00 in a research report issued on Friday,Benzinga reports. The firm ...
Tourmaline Oil Corp. closed 6.2% below its 52-week high of C$70.83, which the company achieved on February 21st.
TOURMALINE BIO ($TRML) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.86 per share, beating estimates of -$0.89 by $0 ...
Readers hoping to buy Tourmaline Oil Corp. ( TSE:TOU ) for its dividend will need to make their move shortly, as ...
Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...
Last week, you might have seen that Tourmaline Oil Corp. ( TSE:TOU ) released its full-year result to the market.